GENERATE BIOMEDICINES INC (GENB)
Health Care · AI-driven drug discovery and development · NASDAQ
An AI-driven drug discovery platform company developing novel therapeutics using generative artificial intelligence and protein design.
What GENERATE BIOMEDICINES INC does
Generate Biomedicines is a clinical-stage biotechnology company that leverages artificial intelligence, machine learning, and protein design to discover and develop novel therapeutic candidates. The company has developed the Generate Platform, a proprietary AI-powered system for identifying and optimizing drug candidates. Generate operates across preclinical and clinical development stages, advancing multiple product candidates through research and development programs aimed at various disease indications.
Themes: []
Fundamentals
- Price$15.72 as of 2026-07-09 close
- Market cap$2.0B as of 2026-07-10
- 1-year return+25.5% as of 2026-07-09 close
- Net margin-637.0% as of 2026-07-10
- ROE-103.7% as of 2026-07-10
- Debt / equity0.01 as of 2026-07-10
- Beta0.57 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.